Physiologically Based Cord Clamping To Improve Neonatal Outcomes After Elective Cesarean Delivery
Launched by QUEEN FABIOLA CHILDREN'S UNIVERSITY HOSPITAL · Feb 19, 2024
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a technique called delayed cord clamping for babies born through planned cesarean delivery. Normally, when a baby is born, the umbilical cord is clamped and cut right away. However, delaying this process can allow more blood to flow from the placenta to the baby, which may help the baby breathe better and adjust more easily after birth. This trial aims to see if this approach helps newborns have better health outcomes and promotes a stronger bond with their mothers right after delivery.
To be eligible for this study, pregnant women must be scheduled for a cesarean section at Brugmann University Hospital and be at least 37 weeks along in their pregnancy. They should be having a single baby and not have any serious health issues or complications that require an emergency cesarean. Participants can expect to have their newborns monitored closely to see how well they adapt after birth, and they will be able to stay connected with their babies during this important time. This research is important because it could improve the early experiences of mothers and their babies following surgical delivery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Pregnant women followed-up in Brugmann University Hospital will be eligible to participate if:
- • 1. Scheduled for cesarean delivery (business days and daily working hours)
- • 2. Singleton pregnancy
- • 3. Cesarean section scheduled at or after 37 weeks gestational age
- Exclusion Criteria:
- • 1. Fetal anomalies (congenital malformations, anemia, growth restriction with abnormal Dopplers)
- • 2. Abnormal placentation (placenta previa)
- • 3. Signs of fetal distress necessitating an emergency cesarean section
- • 4. Spontaneous labor before cesarean section
- • 5. Maternal health issue including severe anemia (defined as hemoglobin level \< 7 g/dL), preeclampsia, and bleeding disorders
- • 6. Maternal refusal of the use of blood products.
- • 7. General anesthesia for cesarian section
- • 8. Planned cord blood banking
- • 9. Total language barrier without possibility of translation
About Queen Fabiola Children's University Hospital
Queen Fabiola Children's University Hospital is a premier pediatric institution dedicated to advancing child health through innovative clinical research and compassionate care. As a leading sponsor of clinical trials, the hospital focuses on developing and evaluating new treatments and therapies for various pediatric conditions. With a multidisciplinary team of experienced clinicians and researchers, the institution fosters a collaborative environment that emphasizes patient safety, ethical standards, and the integration of cutting-edge scientific advancements. Through its commitment to enhancing pediatric healthcare, Queen Fabiola Children's University Hospital aims to improve outcomes for children and adolescents on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, Belgium
Brussels, Belgium
Patients applied
Trial Officials
Anna AMORUSO
Principal Investigator
HUDERF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported